Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy

Journal of Clinical Epidemiology

Volumn 57, Issue 12, 2004, Pages 1237-1243

  Hemminki, Elina ^a   Hovi, Sirpa Liisa ^a,b   Veerus, Piret ^b,c,d   Sevón, Tiina ^a   Tuimala, Risto ^e   Rahu, Mati ^c,d   Hakama, Matti ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^d Estonia   (Estonia)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

@@@Blinding; Hormone therapy; Prevention trial; Recruitment

Indexed keywords

HORMONE; PLACEBO;

ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTONIA; FEMALE; FOLLOW UP; HEALTH SURVEY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ATTITUDE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PATIENT SELECTION; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 11144305819     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2004.04.009     Document Type: Article

References (24)

1. C. Gallo, F. Perrone, S. De Placido, and C. Giusti Informed versus randomised consent to clinical trials Lancet 346 1995 1060 1064
2. L.C. Lovato, Hill, S. Hertert, D.B. Hunninghake, and J.L. Probstfield Recruitment for controlled clinical trials: literature summary and annotated bibliography Control Clin Trials 18 1997 328 352
3. P.M. Ellis Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature Ann Oncol 11 2000 939 945
4. S. Ross, A. Grant, C. Counsell, W. Gillespie, I. Russell, and R. Prescott Barriers to participation in randomised controlled trials: a systematic review J Clin Epidemiol 52 1999 1143 1156
5. R.J. Prescott, C.E. Counsell, W.J. Gillespie, A.M. Grant, I.T. Russell, S. Kiauka, I.R. Colthart, S. Ross, S.M. Shepherd, and D. Russell Factors that limit the quality, number and progress of randomised controlled trials Health Technol Assess 3 20 1999 1 143 (Available from http://www.hta.nhsweb.nhs.uk or http://www.ncchta.org/execsumm/summ320.htm)
6. M.T. Ruffin 4th, and J. Baron Recruiting subjects in cancer prevention and control studies J Cell Biochem Suppl 34 2000 80 83
7. A. Vickers Evaluation of specific and non-specific effects in homeopathy: feasibility study for a randomised trial Br Homeopath J 89 Suppl 1 2000 48 49
8. A. Hrobjartsson What are the main methodological problems in the estimation of placebo effects? J Clin Epidemiol 55 2002 430 435
9. A.J. Vickers, and A.J. de Craen Why use placebos in clinical trials? A narrative review of the methodological literature J Clin Epidemiol 53 2000 157 161
10. J.A. Hall, and M. Dornan Meta-analysis of satisfaction with medical care: description of research domain and analysis of overall satisfaction levels Soc Sci Med 27 1988 637 644
11. J.A. Hall, and M.C. Dornan Patient sociodemographic characteristics as predictors of satisfaction with medical care: A meta-analysis [Erratum in Soc Sci Med 1990;30(12):following 1368.] Soc Sci Med 30 1990 811 818
12. R. Fitzpatrick Scope and measurement of patient satisfaction R. Fitzpatrick A. Hopkins Measurement of patients' satisfaction with their care 1993 Royal College of Physicians of London London 1 17
13. A.J. Welton, M.R. Vickers, J.A. Cooper, T.W. Meade, and T.M. Marteau Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study BMJ 318 1999 1114 1117
14. S.-L. Hovis, T. Karttunen, H. Karro, and E. Hemminki Comparison of Estonain and Finnis physician's opintions of menopause and hormone therapy Maturitas 49 2004 107 113
15. S.J. Rolnick, S.K. Flores, S.E. Fowler, R. Derman, and B. Davidson Conducting randomized, controlled trials. Experience with the dysfunctional uterine bleeding intervention trial J Reprod Med 46 2001 1 5
16. M. Connolly, and T. Low Assessment of patient sociodemographic variables in clinical trials: can patient characteristics make a difference? Ann Acad Med Singapore 29 2000 570 575
17. A. Britton, M. McKee, N. Black, K. McPherson, C. Sanderson, and C. Bain Threats to applicability of randomised trials: exclusions and selective participation J Health Serv Res Policy 4 1999 112 121
18. M. Zelen A new design for randomized clinical trials N Engl J Med 300 1979 1242 1245
19. E. Hemminki, A. Uski, P. Koponen, and U. Rimpelä Iron supplementation during pregnancy: experiences of a randomized trial relying on health service personnel Control Clin Trials 10 1989 290 298
20. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, J. Ockene, and Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
21. I. den Tonkelaar, and B.J. Oddens Determinants of long-term hormone replacement therapy and reasons for early discontinuation Obstet Gynecol 95 2000 507 512
22. C. Li, G. Samsioe, J. Lidfelt, C. Nerbrand, and C.D. Agardh Women's Health in Lund Area (WHILA) Study. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study Menopause 7 2000 273 281
23. D. Pilon, A.-M. Castilloux, and J. Lelorier Estrogen replacement therapy: determinants of persistence with treatment Obstet Gynecol 97 2001 97 100
24. R.F. Reynolds, A.M. Walker, C. Makhlouf Obermeyer, O. Rahman, and D. Guilbert Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO J Clin Epidemiol 54 2001 1056 1064